Larvol Delta - Ankyra-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-Dose-Escalation-Cohort-Evaluating-ANK101-an-Anchored-Immune-Medicine-for-Solid-Tumors

ANK-101 - Ankyra Therap

https://www.businesswire.com/news/home/20240305809178/en/Ankyra-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-Dose-Escalation-Cohort-Evaluating-ANK-101-an-Anchored-Immune-Medicine-for-Solid-Tumors

Mar 5, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next